Metabolomic analysis of percutaneous fine-needle aspiration specimens of thyroid nodules: Potential application for the preoperative diagnosis of thyroid cancer

Article metrics

Abstract

Thyroid nodules are a very common problem. Since malignant thyroid nodules should be treated surgically, preoperative diagnosis of thyroid cancer is very crucial. Cytopathologic analysis of percutaneous fine-needle aspiration (FNA) specimens is the current gold standard for diagnosing thyroid nodules. However, this method has led to high rates of inconclusive results. Metabolomics has emerged as a useful tool in medical fields and shown great potential in diagnosing various cancers. Here, we evaluated the potential of nuclear magnetic resonance (NMR) analysis of percutaneous FNA specimens for preoperative diagnosis of thyroid cancer. We analyzed metabolome of FNA samples of papillary thyroid carcinoma (n = 35) and benign follicular nodule (n = 69) using a proton NMR spectrometer. The metabolomic profiles showed a considerable discrimination between benign and malignant nodules. Receiver operating characteristic (ROC) curve analysis indicated that seven metabolites could serve as discriminators (area under ROC curve value, 0.64–0.85). These findings demonstrated that NMR analysis of percutaneous FNA specimens of thyroid nodules can be potentially useful in the accurate and rapid preoperative diagnosis of thyroid cancer.

Introduction

Thyroid nodules are a very common problem, and they have been detected in up to 67% of the general population with ultrasonography (US) evaluations1,2,3. Cytopathologic analysis of percutaneous fine-needle aspiration (FNA) specimens is the current gold standard for diagnosing thyroid nodules4.

However, this procedure has led to high rates of inconclusive results, including nondiagnostic and atypia of undetermined significance or follicular lesion of undetermined significance5,6,7. For these inconclusive thyroid nodules, the Bethesda system and the majority of guidelines recommend repeat FNA4,5,8. Nevertheless, up to 50% of these repeated examinations continue to yield insufficient or indeterminate results6,7,9. In addition, the false negative rate of cytopathologic analysis has been reported to be up to 10.2%10.

Due to the limitations of conventional cytopathologic analysis, several molecular analyses have been assessed and reported to have some potential as adjuncts to conventional cytopathologic analysis11,12,13,14. However, the results are still unsatisfactory, especially in terms of low sensitivity, negative predictive value, and high cost.

Metabolomics has emerged as a useful tool in multiple medical fields. It has shown great potential in diagnosing various cancers, such as breast, prostate, and colorectal cancers15,16,17,18,19,20. Several articles have presented the potential usefulness of the metabolomic approach for diagnosis of thyroid nodules21,22,23,24,25,26,27. Other than in vivo proton magnetic resonance spectroscopy (1H MRS), which might have limited clinical use, all of the previous studies were based on postoperative surgical specimens. The previous studies did not test the metabolomic approach as a preoperative diagnostic tool for thyroid nodules21,22,23,24,25,26,27. Post-operative specimens may not reflect the actual metabolic signature of thyroid nodules analyzed by the current gold standard, FNA before operation.

Therefore, the purpose of this study was to evaluate the potential of nuclear magnetic resonance (NMR) analysis of percutaneous FNA specimens for preoperative diagnosis of thyroid cancer.

Results

Cytopathologic results of percutaneous FNA samples

Among a total of 230 percutaneous FNA samples, 85 were benign (category II; all consistent with benign follicular nodules) and 53 were malignant (category VI; all papillary thyroid carcinomas) based on cytopathologic analyses according to the Bethesda system5 (Fig. 1).

Figure 1: Flow chart of the study group.
figure1

*Categories were defined according to Bethesda classification.

Among them, 34 could not be analyzed due to the following reasons:

Thirty-four thyroid nodules (16 benign nodules and 18 malignant nodules) were not analyzed because of insufficient FNA sampling amount (n = 29), failed freezing storage of the FNA sample (n = 1), sample loss (n = 1), and insufficient water suppression or shimming (n = 3).

Finally, percutaneous FNA samples of 104 nodules from 100 patients (M:F = 23:77; mean age, 52.9 ± 10.8 years; age range, 21–77 years; four patients with two nodules; 35 malignant nodules from 34 patients and 69 benign nodules from 66 patients) were analyzed using NMR (Fig. 2). The size of the thyroid nodules on US ranged from 3.5 to 27.6 mm (mean, 10.5 ± 6.2 mm) for malignant nodules and from 4.4 to 40.1 mm (mean, 15.2 ± 11.2 mm) for benign nodules. The information of 100 patients enrolled in this study was summarized in Table 1.

Figure 2
figure2

Representative metabolomic spectra from the fine needle aspiration specimens of benign and malignant (papillary thyroid carcinoma [PTC]) thyroid nodules.

Table 1 Demographic and pathologic characteristics of the patients.

Of 35 malignant nodules, 25 nodules of 24 patients underwent surgery. All of these were confirmed to be malignant (papillary thyroid carcinoma).

Of 25 surgically confirmed papillary thyroid carcinomas, the results of BRAFV600E mutation were available in 22 cancers. There were 18 BRAFV600Emutation-positive nodules and four mutation-negative nodules.

Only one of 69 benign nodules underwent surgery because of concomitant thyroid cancer. This case was diagnosed as nodular hyperplasia.

NMR analysis of benign and malignant thyroid nodules

We performed multivariate statistical analysis to discriminate benign and malignant nodules. The orthogonal projections to latent structures-discriminant analysis (OPLS-DA) has been applied because it can discriminate groups in the presence of high structured noise or confounding factors. As indicated in Fig. 3, the OPLS-DA score plot (created using one predictive component and one orthogonal components) shows statistically significant discrimination between benign and malignant nodules with a Q2 value of 0.33 (R2Y = 0.59). In the prediction validation study with three-fold cross-validation, the accuracy, sensitivity, and specificity for diagnosing papillary thyroid carcinoma were 88.6%, 75%, and 95.6%, respectively.

Figure 3: Orthogonal projections to latent structure-discriminant analysis (OPLS-DA) score plot showing the discrimination between benign and malignant (papillary thyroid carcinoma) thyroid nodules.
figure3

The model was obtained using one predictive and one orthogonal components. Benign group: class 1 (black boxes), malignant group: class 2 (red diamonds) Pp represents the predictive component and Po represents the orthogonal component.

Metabolic differences between benign and malignant thyroid nodules

According to OPLS-DA loadings of the predictive latent variable, the relative amounts of lactate (1.3 ppm), choline (3.2 ppm), O-phosphocholine (3.2 ppm), and glycine (3.6 ppm) were greater in malignant nodules than in benign nodules. The relative amounts of citrate (2.6 ppm), glutamine (2.1 ppm), and glutamate (2.0 ppm) were greater in benign nodules than in malignant nodules (Fig. 4). These findings corresponded with the significant metabolites identified in the unpaired Student t test (Table 2).

Figure 4: Identification of metabolites contributing to discriminating model.
figure4

(A) OPLS-DA loading plot showing the metabolites of benign nodules and malignant nodules (papillary thyroid carcinoma) for marker identification. (B) OPLS loading plot (S-TOCSY) showing the model coefficients for each NMR variable. The signals are color coded according to their weights as a discriminator between benign and malignant thyroid nodules. Metabolites that significantly discriminate the two groups were annotated on the model coefficient plot.

Table 2 Relative concentration of metabolites in benign and malignant nodules.

Performance of metabolomic analysis in discriminating between benign and malignant thyroid nodules

For evaluating the discriminating model, we performed the receiver operating characteristic (ROC) curve analysis. The grades predicted by the PLS-DA model showed that area under the curves (AUCs) ranged from 0.64 (glycine; not shown) to 0.85 (citrate). Citrate exhibited the sensitivity of 90% and specificity of 80% (Fig. 5A). To evaluate other marker metabolites, we performed multiple ROC analysis with seven metabolites and the result showed that citrate was the best discriminator (Fig. 5B).

Figure 5: ROC analysis of citrate and multiple marker metabolites.
figure5

(A) The ROC curve of citrate showing the ability as a discriminator of a thyroid nodule. (B) Multiple ROC curve analysis showing that all the seven metabolites had additive values in discriminating benign thyroid nodules from papillary thyroid carcinomas (PTC). The single most important discriminator was citrate which was more abundant in benign thyroid nodules than in PTC.

NMR analysis of BRAF V600E mutation-positive and negative papillary thyroid carcinomas

In the analysis of difference in metabolomic profiles between BRAFV600Emutation-positive papillary thyroid carcinomas and mutation-negative papillary thyroid carcinomas, there were no significant differences because two groups did not separated with negative Q2 value (−0.536) at OPLS-DA analysis.

Discussion

To our knowledge, the current study enrolled the largest number of thyroid nodules for NMR analysis. It was also the first study showing that NMR analysis of percutaneous FNA specimens of thyroid nodules could be applied for preoperative diagnosis of thyroid cancer. Although some previous studies reported that preoperative in vivo1H MRS differentiated between benign and malignant thyroid nodules, this technique cannot be easily applied to patients with thyroid nodules. This is because thyroid nodules are not usually large enough to place voxel for in vivo1H MRS and may be influenced by susceptibility artifact due to their anatomical adjacency to the airway21,23.

Although metabolic analysis usually uses biofluids such as urine, blood, cerebrospinal fluid, and bile juice15,17,19,20, this study was the first to show that FNA specimens of thyroid nodules can be analyzed by NMR for preoperative diagnosis of malignancy. We also proved that only a small amount of FNA specimen sample (20–40 μL) is required for metabolic analysis. A few papers have reported that the metabolic spectral analysis of tissue and FNA specimens from surgically resected thyroid tissues did not significantly differ for diagnosis of papillary thyroid carcinoma22,24.

Although some specimens could not be used for metabolomic analysis in the present study, NMR analysis was performed in approximately 75% of all cases especially with only the remainder of the samples after allotment for conventional cytopathologic analysis. This indicates that the NMR approach is not an extra burden for patients in providing a better diagnosis.

The present study had lower statistical power than previous studies using postsurgical specimens, which had Q2 (R2Y) ranging from 0.37 (0.75) to 0.91 (0.82)25,27. This might be due to the small sample volumes and subsequent lower sensitivity of detection for NMR analysis of percutaneous FNA specimens. Bleeding and contamination with skin, subcutaneous fat, muscle, thyroid capsule, and normal thyroid parenchyma in the course of needle passage may have affected the NMR spectra.

Higher relative concentrations of lactate and choline, and lower relative concentrations of citrate, glutamine, and glutamate in malignant thyroid nodules were found in the present study using preoperative percutaneous FNA specimens. These results are generally concordant with those of several previous in vivo1H MRS studies and studies using surgical specimens21,23,25,26,27,28. This concordance suggests that preoperative metabolomic analysis could be a reliable test for characterizing the pre-operative metabolomic profiles of thyroid nodules.

Lactate concentrations are frequently increased in thyroid cancer and other malignant tumors21,22,23,25,26,29,30,31. Increased lactate level implicates an increase in the glycolytic pathway due to hypoxia or ischemia in tumor tissues or as a result of the Warburg effect25,26,27,29,30,31,32. Lactate was also proven to be a key factor in terms of cancer cell mobility33. Accelerated cancer cell metabolism has also been shown to produce more waste products, such as lactate, for extrusion and neutralization25,32.

Increased glycine in thyroid cancer may also result from increased glycolysis. Many recent studies reported that glycolytic intermediate metabolism plays an important role in tumorigenesis, and one of the main pathways is single carbon metabolism. Recently mitochondrial synthesis and consumption of glycine was proposed to be necessary for rapidly growing cancer cells. And glycine dehydrogenase (GLDC), which cleavages glycine and mediates folate cycle charging, are highly expressed on tumor promoting cells and its enhanced activity is associated with tumorigenesis. Therefore glycine could be one of important metabolites at tumorigenesis with its de novo synthesis and catabolism33,34,35.

Unlike the results of previous studies using postoperative surgical specimens, this study presented that choline was increased in thyroid cancer25,27. Because choline usually forms the phospholipids of cell membranes, malignant tissue cells that have increased multiplication and proliferation can also exhibit increased choline contents (choline phospholipid metabolism in tumor cells), which has been supported in many previous studies of thyroid cancer using MRS21,22,23,26.

Citrate was the most powerful discriminator in the present study. Since proliferating cells exhibit aerobic glycolysis and convert glucose to lactate (lactate fermentation, or the Warburg effect) at high levels, pyruvate-derived citrate synthesis in mitochondria may be reduced in these cells26,36,37. Several recent studies have reported that ATP citrate lyase, which uses citrate to synthesize acetyl CoA in a lipogenesis pathway for cell proliferation, is upregulated in some human cancers such as lung, colorectal, and ovarian cancers. In addition, these studies report that inhibition of ATP citrate lyase suppresses the proliferation of certain types of tumor cells38,39. As noted in these various cancers, proliferating thyroid cancer cells may also use citrate for lipogenesis and may have a lower concentration of citrate compared to that in benign cells.

Recent publications on cell metabolism emphasize that proliferating cells exposed to hypoxic conditions rely almost exclusively on reductive carboxylation of glutamine-glutamate-derived α-ketoglutarate for de novo lipogenesis36,37. Furthermore, some renal cell lines utilize this type of reductive glutamine metabolism even in the normoxic state37. Therefore, several research groups are currently studying the possibility of developing a glutaminase inhibitor as an anti-cancer drug. These observations from earlier studies could possibly explain why proliferating cells or cancer cells might have lower glutamine or glutamate levels than normal cells.

This study has several limitations. First, since the reference used for comparison was based on Bethesda categories II and VI, which show typical benign and malignant cytologic features, the real metabolic spectra of benign and malignant thyroid nodules might be different from our results. Further study with a larger number of nodules should be performed to validate the diagnostic reference.

Second, about 25% of samples (34/138) in the present study could not be used for metabolic analysis. The most important reason was insufficient remaining sample volume after allotment for conventional cytologic analysis. A more delicate preparation method is needed to ensure a sufficient sample amount for both conventional cytologic analysis and NMR analysis. However, in this study, as approximately one third of the thyroid nodules (n = 50) were less than 1 cm which are not usually indicated for FNA, this could also make sample volumes insufficient.

Third, all malignant samples were papillary thyroid carcinomas. Further studies are necessary to evaluate the metabolic profiles of different thyroid neoplasms, such as follicular adenoma, follicular thyroid carcinoma, medullary thyroid carcinoma, and anaplastic thyroid carcinoma.

Fourth, this study failed to reveal the correlation between metabolic spectra and BRAFV600E mutation, a useful prognostic marker for papillary thyroid carcinoma. Further studies using a large number of thyroid nodules should be planned to correlate between various molecular markers and metabolic profiles.

Lastly, studies with a large number of patients should be undertaken to verify the usefulness of NMR analysis in various clinical applications including the nodules with insufficient or indeterminate results and how to use NMR analysis in conjunction with the current cytopapthologic analysis.

In summary, NMR analysis of preoperative percutaneous FNA specimens of thyroid nodules presented different metabolomic profiles for benign and malignant thyroid nodules in this study. NMR analysis of FNA specimens of thyroid nodules may be useful in the accurate and rapid preoperative diagnosis of thyroid cancer.

Methods

Ethics statement

This prospective study was approved by the institutional review board of Seoul National University Hospital. All the methods used in this study were carried out in accordance with the approved guidelines. Informed consent was obtained from all patients.

Study population and acquisition of nuclear magnetic resonance data

From November 2012 to June 2013, 230 nodules of 214 consecutive patients underwent FNA for diagnosis of thyroid nodules and subsequent sampling for NMR analysis by 9 board-certified radiologists specializing in head and neck imaging (mean: 6.4 years, 3–16 years of experience). Patients who had a history of previous FNA, thyroid surgery, or thyroid hormonal treatment were excluded from the study. For patients with multiple thyroid nodules, only the nodules with different ultrasonographic features from one another and located in different thyroid lobes were included.

Under the guidance of high-resolution US machines (IU22, Philips Medical Systems, Bothel, WA; AixPlorer, Supersonic Imagine, Aix en Provence, France; Logiq9, GE Medical Systems, Milwaukee, WI) with 10–12MHz linear transducers, FNA was performed with up to 4 needle passes using capillary or aspiration FNA techniques according to the characteristics of thyroid nodules. Immediately after FNA procedures, aspiration specimens were smeared on a slide, fixed with alcohol, and stained with Papanicolaou for conventional cytologic analysis. The remainders of aspiration specimens were collected in Eppendorf tubes (20–40 μL). The tubes were kept in a dry-ice box and stored in a liquid nitrogen tank until metabolomic analysis was performed.

Cytopathologic analyses were done according to the Bethesda system5. Among the 6 categories, benign (category II) and malignant (category VI) thyroid nodules were chosen for NMR analysis. Furthermore, for surgically confirmed papillary thyroid carcinomas, the BRAFV600E mutation status was analyzed by direct DNA sequencing and metabolomic profiles were analyzed between mutation positive and negative groups.

Samples from thyroid nodules were slowly thawed in an icebox, after which they were centrifuged at 13,000 rpm. The supernatant was collected with a pipette and placed in 1.7-mm SJ tubes with 0.25% trimethylsilane propionic acid (TSP) buffer in D2O to a final volume of 35 μL. The one-dimensional spectra of thyroid samples were measured using an NMR spectrometer (BrukerBiospin, AVIII700, Billerica, MA, USA) equipped with a 1.7-mm PATXI probe operating at a proton NMR frequency of 700.193 MHz.

The acquisition parameters were: pulse, CPMG; time domain size, 32,768; relaxation delay, 2 s; number of scans, 128; spectral width, 14,097 Hz; mixing time, 76 ms; and temperature, 25 °C. The lactate signal (δ = 1.342 ppm) was used as a reference value.

Data processing

All time-domain NMR data underwent Fourier transformation, phase correction, and manual baseline correction. The resulting frequency-domain data were binned at 0.0031-ppm intervals to reduce the complexity of NMR data for pattern recognition. The signals were normalized (area normalization) against total integration values and TSP buffer to exclude the effects of different volumes and NMR measurement variations. Data was then converted into an ASCII text file. The regions corresponding to water (4.71–5.1 ppm) were removed from all spectra. Binning, normalization, and conversion were performed using an in-house Perl program.

Statistical analysis

The signals in specific bins that showed significant differences (P value < 0.05) between benign and malignant groups in terms of area normalization values were determined using the unpaired Student t test. Thereafter, metabolites were identified using Chenomx (Spectral Database, Edmonton, Alberta, Canada) by fitting the experimental spectra (significant signals) to those in the database.

The resultant spectral data sets were then imported into SIMCA-P version 11.0 program (Umetrics, Umeå, Sweden), and mean centering was performed with Pareto scaling for multivariate statistical analysis. Furthermore, OPLS-DA was performed with one predictive component and two orthogonal components for benign and malignant thyroid nodules and also for BRAFV600E mutation positive and negative papillary thyroid carcinomas.

Class discrimination models were created while ensuring that the cross-validated predictability value did not significantly increase to avoid over-fitting of the statistical model. Diagnostic performance was obtained by predicting three-fold cross-validation samples on the basis of a distinction model constructed using the rest of the samples. An a priori cut-off value of 0.5 was used to evaluate the prediction results40. An in-house written R script was used to identify the signals specific for each group by performing the Wilcoxon rank-sum test on all ppm variables (Q2 and R2). Eventually, the specific signals were compared to metabolites identified using the Chenomx data base.

The performance of the prediction derived from OPLS-DA modeling of NMR spectra was evaluated by computing the AUC using an open source ROC curve analysis tool for metabolomics data (ROC Curve Explorer & Tester, www.roccet.ca).

Additional Information

How to cite this article: Ryoo, I. et al. Metabolomic analysis of percutaneous fine-needle aspiration specimens of thyroid nodules: Potential application for the preoperative diagnosis of thyroid cancer. Sci. Rep. 6, 30075; doi: 10.1038/srep30075 (2016).

References

  1. 1

    Frates, M. C. et al. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology 237, 794–800 (2005).

  2. 2

    Moon, W. J. et al. Ultrasonography and the ultrasound-based management of thyroid nodules: consensus statement and recommendations. Korean J Radiol 12, 1–14 (2011).

  3. 3

    Tan, G. H. & Gharib, H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 126, 226–231 (1997).

  4. 4

    American Thyroid Association Guidelines Taskforce on Thyroid, N. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167–1214 (2009).

  5. 5

    Cibas, E. S. & Ali, S. Z. The Bethesda System for Reporting Thyroid Cytopathology. Thyroid 19, 1159–1165 (2009).

  6. 6

    Yang, J., Schnadig, V., Logrono, R. & Wasserman, P. G. Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations. Cancer 111, 306–315 (2007).

  7. 7

    Yassa, L. et al. Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation. Cancer 111, 508–516 (2007).

  8. 8

    Pacini, F. et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154, 787–803 (2006).

  9. 9

    Alexander, E. K. et al. Assessment of nondiagnostic ultrasound-guided fine needle aspirations of thyroid nodules. J Clin Endocrinol Metab 87, 4924–4927 (2002).

  10. 10

    Proietti, A. et al. Molecular characterization of 54 cases of false-negative fine-needle aspiration among 1347 papillary thyroid carcinomas. Cancer Cytopathol 122, 751–759 (2014).

  11. 11

    Alexander, E. K. et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 367, 705–715 (2012).

  12. 12

    Ohori, N. P. et al. BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma. Cancer Cytopathol 121, 197–205 (2013).

  13. 13

    Saleh, H. A., Jin, B., Barnwell, J. & Alzohaili, O. Utility of immunohistochemical markers in differentiating benign from malignant follicular-derived thyroid nodules. Diagn Pathol 5, 9 (2010).

  14. 14

    Xing, M., Haugen, B. R. & Schlumberger, M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 381, 1058–1069 (2013).

  15. 15

    An, Y. J. et al. An NMR metabolomics approach for the diagnosis of leptomeningeal carcinomatosis in lung adenocarcinoma cancer patients. Int J Cancer 136, 162–171 (2015).

  16. 16

    Li, M. et al. An HR-MAS MR metabolomics study on breast tissues obtained with core needle biopsy. PLoS One 6, e25563 (2011).

  17. 17

    Shen, C. et al. Developing urinary metabolomic signatures as early bladder cancer diagnostic markers. OMICS 19, 1–11 (2015).

  18. 18

    Swindle, P. et al. Pathologic characterization of human prostate tissue with proton MR spectroscopy. Radiology 228, 144–151 (2003).

  19. 19

    Wen, H. et al. A new NMR-based metabolomics approach for the diagnosis of biliary tract cancer. J Hepatol 52, 228–233 (2010).

  20. 20

    Zhu, J. et al. Colorectal cancer detection using targeted serum metabolic profiling. J Proteome Res 13, 4120–4130 (2014).

  21. 21

    Gupta, N. et al. Magnetic resonance spectroscopy as a diagnostic modality for carcinoma thyroid. Eur J Radiol 64, 414–418 (2007).

  22. 22

    Jordan, K. W., Adkins, C. B., Cheng, L. L. & Faquin, W. C. Application of magnetic-resonance-spectroscopy- based metabolomics to the fine-needle aspiration diagnosis of papillary thyroid carcinoma. Acta Cytol 55, 584–589 (2011).

  23. 23

    King, A. D. et al. In vivo 1H MR spectroscopy of thyroid carcinoma. Eur J Radiol 54, 112–117 (2005).

  24. 24

    Lean, C. L. et al. Diagnosis of follicular thyroid lesions by proton magnetic resonance on fine needle biopsy. J Clin Endocrinol Metab 80, 1306–1311 (1995).

  25. 25

    Miccoli, P. et al. Metabolomics approach to thyroid nodules: a high-resolution magic-angle spinning nuclear magnetic resonance-based study. Surgery 152, 1118–1124 (2012).

  26. 26

    Tian, Y. et al. Integrative metabonomics as potential method for diagnosis of thyroid malignancy. Scientific reports 5, 14869 (2015).

  27. 27

    Torregrossa, L. et al. Toward the Reliable Diagnosis of Indeterminate Thyroid Lesions: A HRMAS NMR-Based Metabolomics Case of Study. J Proteome Res 11, 3317–3325 (2012).

  28. 28

    Deja, S. et al. Follicular adenomas exhibit a unique metabolic profile. (1)H NMR studies of thyroid lesions. PLoS One 8, e84637 (2013).

  29. 29

    Brizel, D. M. et al. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys 51, 349–353 (2001).

  30. 30

    Tessem, M. B. et al. Discrimination of patients with microsatellite instability colon cancer using 1H HR MAS MR spectroscopy and chemometric analysis. J Proteome Res 9, 3664–3670 (2010).

  31. 31

    Walenta, S., Schroeder, T. & Mueller-Klieser, W. Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology. Curr Med Chem 11, 2195–2204 (2004).

  32. 32

    Koppenol, W. H., Bounds, P. L. & Dang, C. V. Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer 11, 325–337 (2011).

  33. 33

    Kwon, H., Oh, S., Jin, X., An, Y. J. & Park, S. Cancer metabolomics in basic science perspective. Arch Pharm Res 38, 372–380 (2015).

  34. 34

    Jain, M. et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 336, 1040–1044 (2012).

  35. 35

    Zhang, W. C. et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 148, 259–272 (2012).

  36. 36

    DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G. & Thompson, C. B. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7, 11–20 (2008).

  37. 37

    Metallo, C. M. et al. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia. Nature 481, 380–384 (2012).

  38. 38

    Hatzivassiliou, G. et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8, 311–321 (2005).

  39. 39

    Zaidi, N., Swinnen, J. V. & Smans, K. ATP-citrate lyase: a key player in cancer metabolism. Cancer Res 72, 3709–3714 (2012).

  40. 40

    Brindle, J. T. et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 8, 1439–1444 (2002).

Download references

Acknowledgements

This study was supported by research grant 04-2012-104-0 from Seoul National University Hospital Research fund and grants (2009-83533, and 2014M3A9B6069340 to SP) from the National Research Foundation funded by the Ministry of Science, ICT and Future Planning and the Ministry of Education, Science, and Technology of Korea.

Author information

I.R., H.K., S.P. and J.K. conceived the study. I.R. and H.K. wrote the main manuscript text. S.P. and J.K. edited the manuscript considerably. I.R. made Tables 1 and 2 and Figure 1. H.K. made Figures 2,3,45. I.R., H.K., S.C.K., S.C.J., J.A.Y., H.S.S., H.R.C., T.J.Y., S.H.C. and C.S. conducted experiments. I.R. and H.K. analyzed results. All authors reviewed the manuscript.

Correspondence to Sunghyouk Park or Ji-hoon Kim.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.